Metamizole (Dipyrone) and the Liver: A Review of the Literature.
dipyrone
drug metabolism
drug-drug interactions
hepatotoxicity
liver
liver disease
metamizole
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
16
04
2019
accepted:
31
07
2019
pubmed:
23
8
2019
medline:
30
9
2020
entrez:
22
8
2019
Statut:
ppublish
Résumé
Metamizole, also known as dipyrone, was introduced to the market nearly a century ago. Due to its excellent analgesic, antipyretic, and spasmolytic properties combined with its mostly favorable gastrointestinal tolerability, the drug was extensively applied worldwide during the first decades after its market introduction. Although rare, agranulocytosis is a well-known adverse event of metamizole and led to its withdrawal from the market in a number of countries beginning in the 1960s. Nevertheless, metamizole is still a frequently used drug worldwide either legally (by prescription in some countries, over the counter in other countries) or without official approval (especially by immigrants knowing the drug from their home countries) or even illegally (due to its growing application as an adulterant in illicit drugs). Metamizole undergoes extensive metabolism in the liver and cases of potential metamizole-associated hepatotoxicity have been described. Here, the literature is extensively reviewed for the first time regarding hepatic effects associated with the use of metamizole.
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents, Non-Steroidal
0
Antipyretics
0
Nonprescription Drugs
0
Dipyrone
6429L0L52Y
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1433-1442Informations de copyright
© 2019 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology.
Références
Vuik FE, Koehestanie P, Herbers AH, Terhaar Sive Droste JS. Chronic use of metamizole: not so safe after all? Neth J Med. 2017;75(2):81-83.
Gaertner J, Stamer UM, Remi C, et al. Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. Palliat Med. 2017;31(1):26-34.
Miljkovic M, Dragojevic-Simic V, Rancic N, et al. Metamizole utilization and expenditure during 6-year period: Serbia vs. Croatia. Front Public Health. 2018;6:213.
Bagan JV, Lopez Arranz JS, Valencia E, et al. Clinical comparison of dexketoprofen trometamol and dipyrone in postoperative dental pain. J Clin Pharmacol. 1998;38(S1):55S-64S.
Tatsuo MA, Carvalho WM, Silva CV, Miranda AE, Ferreira SH, Francischi JN. Analgesic and antiinflammatory effects of dipyrone in rat adjuvant arthritis model. Inflammation. 1994;18(4):399-405.
de Leeuw TG, Dirckx M, Gonzalez Candel A, Scoones GP, Huygen F, de Wildt SN. The use of dipyrone (metamizol) as an analgesic in children: what is the evidence? A review. Paediatr Anaesth. 2017;27(12):1193-1201.
Drobnik L. [Metamizol in relieving perioperative pain - contemporary look at the traditional medicine]. Anestezjologia i Ratownictwo. 2010;4:40-48.
Nikolova I, Tencheva J, Voinikov J, Petkova V, Benbasat N, Danchev N. Metamizole: a review profile of a well-known “forgotten” drug. Part I: Pharmaceutical and nonclinical profile. Biotechnol Biotechnol Eq. 2012;26(6):3329-3337.
Sanchez S, Alarcon de la Lastra C, Ortiz P, Motilva V, Martin MJ. Gastrointestinal tolerability of metamizol, acetaminophen, and diclofenac in subchronic treatment in rats. Dig Dis Sci. 2002;47(12):2791-2798.
Hinz B, Cheremina O, Bachmakov J, et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J. 2007;21(10):2343-2351.
Kötter T, da Costa BR, Fassler M, et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0122918.
Rodriguez-Martin S, Martin-Merino E, Lerma V, et al. Active surveillance of severe cutaneous adverse reactions: a case-population approach using a registry and a health care database. Pharmacoepidemiol Drug Saf. 2018;27(9):1042-1050.
Achilles A, Mohring A, Dannenberg L, et al. Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. Int J Cardiol. 2017;236:76-81.
Bellegrandi S, Rosso R, Mattiacci G, et al. Combined immediate- and delayed-type hypersensitivity to metamizole. Allergy. 1999;54(1):88-90.
Ariza A, Garcia-Martin E, Salas M, et al. Pyrazolones metabolites are relevant for identifying selective anaphylaxis to metamizole. Sci Rep. 2016;6:23845.
Benjamin JE, Biederman JB. Agranulocytic leukopenia induced by a drug related to aminopyrine. JAMA. 1936;107(7):493-494.
Rollason V, Desmeules JA. Use of metamizole in children and the risk of agranulocytosis: is the benefit worth the risk? Eur J Anaesthesiol. 2015;32(12):837-838.
Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657-665.
Blaser L, Hassna H, Hofmann S, et al. Leucopenia associated with metamizole: a case-control study. Swiss Med Wkly. 2017;147:w14438.
Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology Am Soc Hematol Educ Program. 2017;2017(1):187-193.
Garbe E. Non-chemotherapy drug-induced agranulocytosis. Expert Opin Drug Saf. 2007;6(3):323-335.
Huber M, Andersohn F, Bronder E, et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur J Clin Pharmacol. 2014;70(3):339-345.
Blaser LS, Tramonti A, Egger P, Haschke M, Krahenbuhl S, Ratz Bravo AE. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol. 2015;71(2):209-217.
Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA. 1986;256(13):1749-1757.
Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002;58(4):265-274.
Kiatboonsri P, Richter J. Dipyrone trials in Thailand. Lancet. 1989;2(8654):107.
Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016;41(5):459-477.
Preissner S, Siramshetty VB, Dunkel M, Steinborn P, Luft FC, Preissner R. Pain-prescription differences - an analysis of 500,000 discharge summaries. Curr Drug Abuse Rev. 2018;11(1):58-66.
WITHDRAWN: a resource for withdrawn and discontinued drugs. Metamizole-legal status. http://cheminfo.charite.de/withdrawn/metamizole.html. Published September 2015. Accessed April 15, 2019.
Nikolova I, Petkova V, Tencheva J, Benbasat N, Voinikov J, Danchev N. Metamizole: a review profile of a well-known “forgotten” drug. Part II: Clinical profile. Biotechnol Biotechnol Eq. 2013;27(2):3605-3619.
Bhaumik S. India's health ministry bans pioglitazone, metamizole, and flupentixol-melitracen. BMJ. 2013;347:f4366.
Reist L, Erlenwein J, Meissner W, Stammschulte T, Stuber F, Stamer UM. Dipyrone is the preferred nonopioid analgesic for the treatment of acute and chronic pain: a survey of clinical practice in German-speaking countries. Eur J Pain. 2018;22(6):1103-1112.
Prado MA, Francisco PM, Bastos TF, Barros MB. Use of prescription drugs and self-medication among men. Rev Bras Epidemiol. 2016;19(3):594-608.
Lima EDC, Matos GC, Vieira JML, Goncalves I, Cabral LM, Turner MA. Suspected adverse drug reactions reported for Brazilian children: cross-sectional study [published online ahead of print July 18, 2018]. J Pediatr (Rio J). https://doi.org/10.1016/j.jped.2018.05.019.
Tulunay FC, Ergun H, Gulmez SE, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. Funct Neurol. 2004;19(3):197-202.
Wertli MM, Reich O, Signorell A, Burgstaller JM, Steurer J, Held U. Changes over time in prescription practices of pain medications in Switzerland between 2006 and 2013: an analysis of insurance claims. BMC Health Serv Res. 2017;17(1):167.
Pastore GP, Goulart DR, Pastore PR, Prati AJ, de Moraes M. Self-medication among myofascial pain patients: a preliminary study. Open Dent J. 2018;12:347-353.
Arrais PS, Fernandes ME, Pizzol TD, et al. Prevalence of self-medication in Brazil and associated factors. Rev Saude Publica. 2016;50(suppl 2):13s.
da Silva Dal Pizzol T, Turmina Fontanella A, Cardoso Ferreira MB, Damaso Bertoldi A, Boff Borges R, Serrate Mengue S. Analgesic use among the Brazilian population: results from the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM). PLoS One. 2019;14(3):e0214329.
Ly N. Account for all medications, even if they're banned. J Fam Pract. 2016;65(7):437.
Garcia S, Canoniero M, Lopes G, Soriano AO. Metamizole use among Hispanics in Miami: report of a survey conducted in a primary care setting. South Med J. 2006;99(9):924-926.
Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to “Mexican aspirin” (dipyrone). South Med J. 1996;89(6):612-614.
Bonkowsky JL, Frazer JK, Buchi KF, Byington CL. Metamizole use by Latino immigrants: a common and potentially harmful home remedy. Pediatrics. 2002;109(6):e98.
Hearn L, Derry S, Moore RA. Single dose dipyrone (metamizole) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2016;4:CD011421.
Bensenor IM. Dipyrone and blood dyscrasia revisited: “non-evidence based medicine.” Sao Paulo Med J. 2005;123(3):99-100.
Ruiz-Arguelles GJ, Alarcon-Segovia D. “Mexican Aspirin”-a derogatory term. Am J Hematol. 1990;34(2):159-160.
Weinert PL, Pezza L, Pezza HR. A simplified reflectometric method for the rapid determination of dipyrone in pharmaceutical formulations. J Braz Chem Soc. 2007;18(4):846-854.
Chotimah C, Sudjadi, Riyanto S, Rohman A. Simultaneous determination of metamizole, thiamin and pyridoxin using UV-spectroscopy in combination with multivariate calibration. Adv Pharm Bull. 2015;5(4):593-598.
Isaacs RCA, Harper MM, Miller EC. Analytical challenges in the confirmative identification of dipyrone as an adulterant in illicit drug samples. Forensic Sci Int. 2017;270:185-192.
Broseus J, Gentile N, Esseiva P. The cutting of cocaine and heroin: a critical review. Forensic Sci Int. 2016;262:73-83.
Fucci N, De Giovanni N. Adulterants encountered in the illicit cocaine market. Forensic Sci Int. 1998;95(3):247-252.
Marcelo MCA, Fiorentin TR, Mariotti KC, Ortiz RS, Limberger RP, Ferrãoa MF. Determination of cocaine and its main adulterants in seized drugs from Rio Grande do Sul, Brazil, by a Doehlert optimized LC-DAD method. Anal Methods. 2016;8:5212-5217.
Giorgi M, Lebkowska-Wieruszewska B, Lisowski A, et al. Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs. J Vet Pharmacol Ther. 2018;41(3):428-436.
Ergün H, Uzbay IT, Celik T, Kayir H, Yesilyurt O, Tulunay FC. Dipyrone inhibits ethanol withdrawal and pentylenetetrazol-induced seizures in rats. Drug Dev Res. 2001;53:254-259.
Malvar Ddo C, Aguiar FA, Vaz Ade L, et al. Dipyrone metabolite 4-MAA induces hypothermia and inhibits PGE2-dependent and -independent fever while 4-AA only blocks PGE2-dependent fever. Br J Pharmacol. 2014;171(15):3666-3679.
Vlahov V, Badian M, Verho M, Bacracheva N. Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium. Eur J Clin Pharmacol. 1990;38(1):61-65.
Konijnenbelt-Peters J, van der Heijden C, Ekhart C, Bos J, Bruhn J, Kramers C. Metamizole (dipyrone) as an alternative agent in postoperative analgesia in patients with contraindications for nonsteroidal anti-inflammatory drugs. Pain Pract. 2017;17(3):402-408.
Artaza MA, Puerta JL, Ortiz R, Laporte JR. Bioavailability of two metamizole (dipyrone) solutions as single doses of 2 g versus metamizole capsules. Int J Clin Pharmacol Ther. 2002;40(7):322-326.
Taylor J, Mellstrom B, Fernaud I, Naranjo JR. Metamizol potentiates morphine effects on visceral pain and evoked c-Fos immunoreactivity in spinal cord. Eur J Pharmacol. 1998;351(1):39-47.
Flusser D, Zylber-Katz E, Granit L, Levy M. Influence of food on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol. 1988;34(1):105-107.
Moore RA, Derry S, Wiffen PJ, Straube S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Br J Clin Pharmacol. 2015;80(3):381-388.
Zylber-Katz E, Granit L, Stessman J, Levy M. Effect of age on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol. 1989;36(5):513-516.
Suarez-Kurtz G, Ribeiro FM, Estrela RC, Vicente FL, Struchiner CJ. Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone. Braz J Med Biol Res. 2001;34(11):1475-1485.
Cohen O, Zylber-Katz E, Caraco Y, Granit L, Levy M. Cerebrospinal fluid and plasma concentrations of dipyrone metabolites after a single oral dose of dipyrone. Eur J Clin Pharmacol. 1998;54(7):549-553.
Bachmann F, Duthaler U, Rudin D, Krahenbuhl S, Haschke M. N-demethylation of N-methyl-4-aminoantipyrine, the main metabolite of metamizole. Eur J Pharm Sci. 2018;120:172-180.
Saussele T, Burk O, Blievernicht JK, et al. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther. 2007;82(3):265-274.
Lampl C, Likar R. [Metamizole (dipyrone): mode of action, drug-drug interactions, and risk of agranulocytosis]. Schmerz. 2014;28(6):584-590.
Cazacu I, Mogosan C, Loghin F. Safety issues of current analgesics: an update. Clujul Med. 2015;88(2):128-136.
Pfrepper C, Deters S, Metze M, Siegemund R, Gockel I, Petros S. Metamizole inhibits arachidonic acid-induced platelet aggregation after surgery and impairs the effect of aspirin in hospitalized patients. Eur J Clin Pharmacol. 2019.
Sigaroudi A, Jetter A, Mueller TF, Kullak-Ublick G, Weiler S. Severe reduction in tacrolimus concentrations with concomitant metamizole (dipyrone) therapy in transplant patients. Eur J Clin Pharmacol. 2019.
Martinez C, Andreu I, Amo G, et al. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol. 2014;92(3):457-466.
Caraco Y, Zylber-Katz E, Fridlander M, Admon D, Levy M. The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. Eur J Clin Pharmacol. 1999;55(6):475-478.
Rogosch T, Sinning C, Podlewski A, et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorg Med Chem. 2012;20(1):101-107.
Levy M, Flusser D, Zylber-Katz E, Granit L. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol. 1984;27(4):453-458.
Zylber-Katz E, Granit L, Levy M. Formation and excretion of dipyrone metabolites in man. Eur J Clin Pharmacol. 1992;42(2):187-191.
Bacracheva N, Vlahov V. The acetylation phenotype: does it contribute to the non-linearity of the metabolite pharmacokinetics of metamizol? Eur J Clin Pharmacol. 1995;48(1):79-80.
Vlahov V, Bacracheva N, Tontcheva D, et al. Genetic factors and risk of agranulocytosis from metamizol. Pharmacogenetics. 1996;6(1):67-72.
dos Santos GG, Dias EV, Teixeira JM, et al. The analgesic effect of dipyrone in peripheral tissue involves two different mechanisms: neuronal K(ATP) channel opening and CB(1) receptor activation. Eur J Pharmacol. 2014;741:124-131.
Volz M, Kellner HM. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol. 1980;10(Suppl 2):299S-308S.
Kraul H, Pasanen M, Sigusch H, et al. Immunohistochemical properties of dipyrone-induced cytochromes P450 in rats. Hum Exp Toxicol. 1996;15(1):45-50.
Geisslinger G, Bocker R, Levy M. High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Pharm Res. 1996;13(8):1272-1275.
Zylber-Katz E, Granit L, Levy M. Plasma protein binding of dipyrone metabolites in man. Eur J Clin Pharmacol. 1985;29(1):67-71.
Lüthy C, Multhaupt M, Oetliker O, Perisic M. Differential effect of acetylsalicylic acid and dipyrone on prostaglandin production in human fibroblast cultures. Br J Pharmacol. 1983;79(4):849-854.
Uramaru N, Shigematsu H, Toda A, Eyanagi R, Kitamura S, Ohta S. Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics. J Med Chem. 2010;53(24):8727-8733.
Uetrecht JP, Ma HM, MacKnight E, McClelland R. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem Res Toxicol. 1995;8(2):226-233.
Costa D, Vieira A, Fernandes E. Dipyrone and aminopyrine are effective scavengers of reactive nitrogen species. Redox Rep. 2006;11(3):136-142.
Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone metabolism in liver disease. Clin Pharmacol Ther. 1995;58(2):198-209.
Levy M, Leibowich I, Zylber-Katz E, et al. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus. Clin Pharmacol Ther. 1997;62(1):6-14.
Levy M, Safadi R, Zylber-Katz E, Granit L, Caraco Y. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators. Eur J Clin Pharmacol. 2001;57(6-7):461-465.
Jasiecka A, Maslanka T, Jaroszewski JJ. Pharmacological characteristics of metamizole. Pol J Vet Sci. 2014;17(1):207-214.
Benesic A, Rotter I, Dragoi D, Weber S, Buchholtz ML, Gerbes AL. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2018;16(9):1488-1494 e1485.
Haase D, Hübner S, Kunellis S, Kotzerke G, König H. Metamizol suicide - lethal outcome despite maximum therapy. Toxichem Krimtech. 2012;79(2):71-80.
Federmann G, Becker EW, Tautorat H, Penschuck C, Berg PA. [Demonstration by lymphocyte transformation test of the allergic genesis in a case of acute hepatitis]. Dtsch Med Wochenschr. 1988;113(43):1676-1679.
Herdeg C, Hilt F, Buchtemann A, Bianchi L, Klein R. Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test. Liver. 2002;22(6):507-513.
Elzagallaai AA, Rieder MJ. In vitro testing for diagnosis of idiosyncratic adverse drug reactions: implications for pathophysiology. Br J Clin Pharmacol. 2015;80(4):889-900.
Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-1444.
Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730-742.
Okonek S, Reinecke HJ. Acute toxicity of pyrazolones. Am J Med. 1983;75(5A):94-98.
Ackerman Z, Flugelman MY, Wax Y, Shouval D, Levy M. Hepatitis during measles in young adults: possible role of antipyretic drugs. Hepatology. 1989;10(2):203-206.
Dinh A, Fleuret V, Hanslik T. Liver involvement in adults with measles. Int J Infect Dis. 2013;17(12):e1243-e1244.
Thornton J. Measles cases in Europe tripled from 2017 to 2018. BMJ. 2019;364:l634.
Sundaram ME, Guterman LB, Omer SB. The true cost of measles outbreaks during the postelimination era. JAMA. 2019;321(12):1155-1156.
Sabaté M, Ibanez L, Perez E, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther. 2007;25(12):1401-1409.
Douros A, Bronder E, Andersohn F, et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol. 2015;79(6):988-999.
Duarte Souza JF, Lajolo PP, Pinczowski H, Del Giglio A. Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better. Support Care Cancer. 2007;15(11):1319-1323.
Rodriguez M, Barutell C, Rull M, et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. Eur J Cancer. 1994;30A(5):584-587.
Yalcin S, Gullu IH, Tekuzman G, Savas C, Firat D. A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. Am J Clin Oncol. 1998;21(2):185-188.
Yalcin S, Gullu I, Tekuzman G, Savas C. Ketorolac tromethamine in cancer pain. Acta Oncol. 1997;36(2):231-232.